Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs Adalimumab in Juvenile Psoriatic Arthritis
NCT06100744Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of risankizumab in juvenile psoriatic arthritis (JPsA), sponsored by AbbVie Inc.. Started Jul 2024; status: recruiting.
02
Drugs
risankizumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT06100744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100744.